Literature DB >> 22941524

Pseudobulbar affect: burden of illness in the USA.

Jennifer Colamonico1, Andrea Formella, Walter Bradley.   

Abstract

INTRODUCTION: Pseudobulbar affect (PBA) is characterized by involuntary and uncontrollable laughing and/or crying episodes, occurring secondary to neurological disease or injury. The impact of PBA on social and occupational function, health status, quality of life (QOL), and quality of relationships (QOR) is not well studied.
METHODS: This US survey conducted by Harris Interactive compared health status and daily function of patients with and without PBA. Eligible respondents were Harris Panel Online registrants previously diagnosed with stroke, multiple sclerosis, Parkinson's disease, Alzheimer's disease, traumatic brain injury, or amyotrophic lateral sclerosis, or primary, nonpaid caregivers for such patients who were too debilitated to participate. PBA was identified by a Center for Neurologic Study lability scale score of 13 or greater. Measures included the 36-item short form health survey (SF-36), the work productivity and impairment (WPAI) questionnaire, visual analog scales (VAS) for impact of PBA symptoms on QOL and QOR, and customized questions related to burden and impact of involuntary laughing/crying episodes on patients' lives. Survey responses were weighted to adjust for the relative proportion of the primary neurological conditions in the overall population and between group differences in patient age and gender. PBA and non-PBA group responses were compared using two-tailed t tests adjusted for severity of the primary neurological conditions.
RESULTS: The 1,052 respondents included 399 PBA group participants and 653 controls. The PBA group showed significantly worse scores versus non-PBA controls on component and summary SF-36 scores (P<0.05 for all), VAS scores (P<0.05 for both), and WPAI scores (P<0.05). Among PBA group respondents, PBA contributed a great deal to or was the main cause of patients becoming housebound for 24% and being moved to supervised living placement for 9% of respondents.
CONCLUSION: PBA is associated with considerable burden incremental to that of the underlying neurological conditions, affecting QOL, QOR, health status, and social and occupational functioning.

Entities:  

Mesh:

Year:  2012        PMID: 22941524     DOI: 10.1007/s12325-012-0043-7

Source DB:  PubMed          Journal:  Adv Ther        ISSN: 0741-238X            Impact factor:   3.845


  16 in total

1.  Pseudobulbar affect (PBA) in an incident ALS cohort: results from the Apulia registry (SLAP).

Authors:  Rosanna Tortelli; Massimiliano Copetti; Simona Arcuti; Marianna Tursi; Annalisa Iurillo; Maria Rosaria Barulli; Rosa Cortese; Rosa Capozzo; Eustachio D'Errico; Benoit Marin; Isabella Laura Simone; Giancarlo Logroscino
Journal:  J Neurol       Date:  2015-11-20       Impact factor: 4.849

Review 2.  Patient-Perceived Outcomes and Quality of Life in ALS.

Authors:  Zachary Simmons
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

3.  Pharmacotherapy for the Pseudobulbar Affect in Individuals Who Have Sustained a Traumatic Brain Injury: a Systematic Review.

Authors:  Amelia J Hicks; Fiona J Clay; Jennie L Ponsford; Luke A Perry; Mahesh Jayaram; Rachel Batty; Malcolm Hopwood
Journal:  Neuropsychol Rev       Date:  2020-01-15       Impact factor: 7.444

4.  Posterior Fossa Lesion Load and Pathological Laughing and Crying in Multiple Sclerosis.

Authors:  Jacqueline A Luhoway; Manas Sharma; Suresh Menon; Heather Rosehart; Sarah A Morrow
Journal:  Int J MS Care       Date:  2019 May-Jun

5.  Pharmaceutical interventions for emotionalism after stroke.

Authors:  Sabine Allida; Kulsum Patel; Allan House; Maree L Hackett
Journal:  Cochrane Database Syst Rev       Date:  2019-03-19

6.  Persistent pseudobulbar affect secondary to acute disseminated encephalomyelitis.

Authors:  Zhendong Li; Shijian Luo; Jianying Ou; Rihe Huang; Ying Wang
Journal:  Socioaffect Neurosci Psychol       Date:  2015-03-18

7.  PRISM: a novel research tool to assess the prevalence of pseudobulbar affect symptoms across neurological conditions.

Authors:  Benjamin Rix Brooks; David Crumpacker; Jonathan Fellus; Daniel Kantor; Randall E Kaye
Journal:  PLoS One       Date:  2013-08-21       Impact factor: 3.240

Review 8.  Review of Dextromethorphan 20 mg/Quinidine 10 mg (NUEDEXTA(®)) for Pseudobulbar Affect.

Authors:  Erik P Pioro
Journal:  Neurol Ther       Date:  2014-06-17

Review 9.  Diagnosing pseudobulbar affect in traumatic brain injury.

Authors:  William Engelman; Flora M Hammond; James F Malec
Journal:  Neuropsychiatr Dis Treat       Date:  2014-10-07       Impact factor: 2.570

Review 10.  Pseudobulbar affect: prevalence and management.

Authors:  Aiesha Ahmed; Zachary Simmons
Journal:  Ther Clin Risk Manag       Date:  2013-11-29       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.